Toblli Jorge E, Cao Gabriel, Angerosa Margarita
Laboratory of Experimental Medicine, Hospital Alemán, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
Drug Des Devel Ther. 2015 May 7;9:2585-97. doi: 10.2147/DDDT.S81863. eCollection 2015.
Iron deficiency is common in inflammatory bowel disease, yet oral iron therapy may worsen the disease symptoms and increase systemic and local oxidative stress. The aim of this study was to compare the effects of oral ferrous sulfate and iron polymaltose complex on inflammatory and oxidative stress markers in colitic rats.
Animals were divided into four groups with ten animals each. Rats of three groups received dextran sodium sulfate to induce colitis and animals of two of these groups received 5 mg iron/kg of body weight a day, as ferrous sulfate or iron polymaltose complex, for 7 days. Gross colon anatomy, histology of colon and liver, stainings of L-ferritin, Prussian blue, hepcidin, tumor necrosis factor-α, and interleukin-6, as well serum levels of liver enzymes, inflammatory markers, and iron markers, were assessed.
Body weight, gross anatomy, crypt injury and inflammation scores, inflammatory parameters in liver and colon, as well as serum and liver hepcidin levels were not significantly different between colitic animals without iron treatment and colitic animals treated with iron polymaltose complex. In contrast, ferrous sulfate treatment caused significant worsening of these parameters. As opposed to ferrous sulfate, iron polymaltose complex caused less or no additional oxidative stress in the colon and liver compared to colitic animals without iron treatment.
Iron polymaltose complex had negligible effects on colonic tissue erosion, local or systemic oxidative stress, and local or systemic inflammation, even at high therapeutic doses, and may thus represent a valuable oral treatment of iron deficiency in inflammatory bowel disease.
缺铁在炎症性肠病中很常见,但口服铁剂治疗可能会使疾病症状恶化,并增加全身和局部氧化应激。本研究的目的是比较口服硫酸亚铁和聚麦芽糖铁复合物对结肠炎大鼠炎症和氧化应激标志物的影响。
将动物分为四组,每组十只。三组大鼠接受葡聚糖硫酸钠诱导结肠炎,其中两组动物每天接受5mg/kg体重的铁,以硫酸亚铁或聚麦芽糖铁复合物的形式,持续7天。评估结肠大体解剖、结肠和肝脏组织学、L-铁蛋白、普鲁士蓝、铁调素、肿瘤坏死因子-α和白细胞介素-6染色,以及肝酶、炎症标志物和铁标志物的血清水平。
未接受铁治疗的结肠炎动物与接受聚麦芽糖铁复合物治疗的结肠炎动物在体重、大体解剖、隐窝损伤和炎症评分、肝脏和结肠的炎症参数以及血清和肝脏铁调素水平方面无显著差异。相比之下,硫酸亚铁治疗使这些参数显著恶化。与硫酸亚铁不同,与未接受铁治疗的结肠炎动物相比,聚麦芽糖铁复合物在结肠和肝脏中引起的额外氧化应激较少或没有。
即使在高治疗剂量下,聚麦芽糖铁复合物对结肠组织糜烂、局部或全身氧化应激以及局部或全身炎症的影响也可忽略不计,因此可能是炎症性肠病缺铁的一种有价值的口服治疗方法。